Innovent Biologics Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
5,659
- Stock Symbol
-
01801
- Investments
-
5
- Share Price
-
$6.76
- (As of Tuesday Closing)
Innovent Biologics General Information
Description
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has 12 commercialized oncology products and three commercialized nononcology products as of March 2025. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Contact Information
Website
www.innoventbio.comCorporate Office
- 999 Jinguang Road
- Minhang
- Shanghai, Jiangsu 201100
- China
Corporate Office
- 999 Jinguang Road
- Minhang
- Shanghai, Jiangsu 201100
- China
Innovent Biologics Timeline
Innovent Biologics Stock Performance
As of 22-Apr-2025, Innovent Biologics’s stock price is $6.76. Its current market cap is $11B with 1.63B shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.76 | $6.09 | $3.68 - $6.81 | $11B | 1.63B | 17.3M |
Innovent Biologics Financials Summary
As of 31-Dec-2024, Innovent Biologics has a trailing 12-month revenue of $1.31B.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 6,997,928 | 6,997,928 | 8,233,917 | 5,957,729 |
| Revenue | 1,313,071 | 1,313,071 | 877,198 | 676,569 |
| EBITDA | (1,529) | (157,391) | (287,902) | |
| Net Income | (13,188) | (13,188) | (145,291) | (323,596) |
| Total Assets | 2,959,220 | 2,959,220 | 2,909,934 | 2,549,367 |
| Total Debt | 387,809 | 387,809 | 510,754 | 467,947 |
Innovent Biologics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Innovent Biologics Comparisons
Industry
Financing
Details
Innovent Biologics Competitors (51)
One of Innovent Biologics’s 51 competitors is Abbisko Therapeutics, a Formerly VC-backed company based in Shanghai, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Abbisko Therapeutics | Formerly VC-backed | Shanghai, China | ||||
| CStone Pharmaceuticals | Formerly VC-backed | Suzhou, China | ||||
| Alphamab Oncology | Formerly VC-backed | Suzhou, China | ||||
| BeiGene | Formerly PE-Backed | Beijing, China | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA |
Innovent Biologics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Innovent Biologics Patents
Innovent Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023310539-A1 | Mutant promoting homologous pairing of heavy and light chains of multispecific antibody | Pending | 22-Jul-2022 | ||
| AU-2023281591-A1 | Treatment method using mazdutide | Pending | 01-Jun-2022 | ||
| EP-4534095-A2 | Treatment method using mazdutide | Pending | 01-Jun-2022 | ||
| US-20250073347-A1 | Antibody-drug conjugate targeting claudin18.2 | Pending | 17-Dec-2021 | ||
| AU-2022405415-A1 | Antibody binding to bcma and use thereof | Pending | 07-Dec-2021 | C07K16/2878 |
Innovent Biologics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Innovent Biologics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Innovent Biologics Investments (5)
Innovent Biologics’s most recent deal was a Later Stage VC with IASO Bio. The deal was made on 05-Jul-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| IASO Bio | 05-Jul-2024 | Later Stage VC | Drug Discovery | ||
| Affini-T | 17-Mar-2022 | Early Stage VC | Biotechnology | ||
| Etana Biotech | 14-Sep-2021 | Later Stage VC | Biotechnology | ||
| AnHeart Therapeutics | 01-Sep-2021 | Early Stage VC | Biotechnology | ||
| Ascentage Pharma | 14-Jul-2021 | PIPE | Drug Discovery |
Innovent Biologics ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
29.28 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Biotechnology
Subindustry
of 371
Rank
Percentile
Innovent Biologics Exits (1)
Innovent Biologics’s most recent exit was on 01-Sep-2021 from AnHeart Therapeutics. The exit was categorized as with 5 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| AnHeart Therapeutics | 01-Sep-2021 | Completed |
|
Innovent Biologics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| InnoPinnacle | Suzhou, China |
Innovent Biologics FAQs
-
When was Innovent Biologics founded?
Innovent Biologics was founded in 2011.
-
Where is Innovent Biologics headquartered?
Innovent Biologics is headquartered in Shanghai, China.
-
What is the size of Innovent Biologics?
Innovent Biologics has 5,659 total employees.
-
What industry is Innovent Biologics in?
Innovent Biologics’s primary industry is Pharmaceuticals.
-
Is Innovent Biologics a private or public company?
Innovent Biologics is a Public company.
-
What is Innovent Biologics’s stock symbol?
The ticker symbol for Innovent Biologics is 01801.
-
What is the current stock price of Innovent Biologics?
As of 22-Apr-2025 the stock price of Innovent Biologics is $6.76.
-
What is the current market cap of Innovent Biologics?
The current market capitalization of Innovent Biologics is $11B.
-
What is Innovent Biologics’s current revenue?
The trailing twelve month revenue for Innovent Biologics is $1.31B.
-
Who are Innovent Biologics’s competitors?
Abbisko Therapeutics, CStone Pharmaceuticals, Alphamab Oncology, BeiGene, and Dicerna Pharmaceuticals are some of the 51 competitors of Innovent Biologics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
